Third-party logistics in the pharmaceutical industry must always be considered a strategic partnership, not a transactional handoff. Today’s 3PL is no longer about outsourcing a non-core function. It is about orchestrating a regulated, data-rich, end-to-end value chain.
Danny Williams, President of Channel Management & 3PL with EVERSANA, recently was one of several experts interviewed by Pharmaceutical Commerce in their annual focus on 3PLs.
As he discussed, today’s modern 3PL providers supports the full order-to-cash lifecycle by integrating supply chain operations, quality, data, and revenue management in a way that is adaptable and scalable. This enables pharmaceutical manufacturers, particularly those without established infrastructure, to remain focused on discovering and developing therapies for patients in need.
“Pharmaceutical 3PL is no longer about moving product. It’s about orchestrating a regulated, data‑rich value chain that ensures therapies reach patients on time, every time.” – Danny Williams, President, Channel Management & 3PL, EVERSANA
What should manufacturers look for in a 3PL partner?
When selecting a 3PL partner, manufacturers should avoid thinking in terms of pick, pack, and ship. The more important question is whether a provider offers an integrated approach to commercialization that aligns with a product’s launch and long-term growth strategy.
Experience within the pharmaceutical supply chain, capabilities aligned to specific therapies or channels, and accessible leadership all matter. A proven track record is equally important. Accuracy rates, on-time delivery performance, launch experience, and the ability to adapt to disruptions such as weather events, manufacturing delays, or labor challenges all signal whether a 3PL can deliver with confidence.
What Trends will shape pharmaceutical 3PL in 2026 and beyond?
The rise of biologics and cell and gene therapies continue to drive demand for refrigerated, frozen, and deep-frozen storage, making advanced cold chain capabilities a baseline requirement. At the same time, more brands are adopting direct-to-patient models that integrate telehealth, e-prescribing, and home delivery. On- and near-shoring initiatives in the U.S. are also increasing demand for warehousing and faster cycle times.
As therapies grow more complex and channels diversify, pharmaceutical 3PLs will continue evolving from vendors into strategic partners, helping manufacturers navigate complexity and bring therapies to patients with confidence.
Learn more about our integrated 3PL and Channel Management solutions.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…